| Nov 20 |
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
|
| Nov 20 |
If RFK Jr. Cuts Science Funding, These Instrument Makers May Suffer
|
| Nov 20 |
Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)
|
| Nov 20 |
Illumina gear up to expand TruSight Oncology portfolio
|
| Nov 20 |
ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio
|
| Nov 19 |
Illumina announces expansion of TruSight Oncology portfolio
|
| Nov 18 |
Is Illumina, Inc. (ILMN) the Best Immunotherapy Stock to Buy Now?
|
| Nov 15 |
Life sciences stocks viewed positively at TD Cowen despite post-election weakness
|
| Nov 12 |
Illumina coverage resumed at equal weight by Morgan Stanley
|
| Nov 12 |
Illumina, Inc. (ILMN): Unlocking Growth Potential in Genetic Testing and Robotics
|
